Compare CRL & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | DVA |
|---|---|---|
| Founded | 1947 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.4B |
| IPO Year | 2000 | 1995 |
| Metric | CRL | DVA |
|---|---|---|
| Price | $195.57 | $115.91 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | ★ $191.00 | $145.00 |
| AVG Volume (30 Days) | 794.4K | ★ 979.6K |
| Earning Date | 11-05-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.63 |
| EPS | N/A | ★ 9.76 |
| Revenue | $4,023,704,000.00 | ★ $13,317,965,000.00 |
| Revenue This Year | N/A | $6.50 |
| Revenue Next Year | $1.66 | $2.97 |
| P/E Ratio | ★ N/A | $12.13 |
| Revenue Growth | N/A | ★ 5.14 |
| 52 Week Low | $91.86 | $113.97 |
| 52 Week High | $200.58 | $179.60 |
| Indicator | CRL | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 65.20 | 39.90 |
| Support Level | $194.50 | $115.91 |
| Resistance Level | $200.58 | $122.40 |
| Average True Range (ATR) | 5.45 | 2.58 |
| MACD | 1.24 | 0.13 |
| Stochastic Oscillator | 79.95 | 10.01 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.